Brief: Arrowhead Pharmaceuticals submits New Drug Application To U.S. FDA
18/11/2024 12:42
Nov 18 (Reuters) - Arrowhead Pharmaceuticals Inc
ARWR.O :
* ARROWHEAD PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO
U.S.
FDA FOR PLOZASIRAN FOR THE TREATMENT OF FAMILIAL CHYLOMICRONEMIA
SYNDROME
* ARROWHEAD PHARMACEUTICALS INC - TO SUBMIT PLOZASIRAN
APPLICATIONS TO OTHER REGULATORS IN 2025
* ARROWHEAD PHARMACEUTICALS INC - PALISADE STUDY MET PRIMARY
AND
SECONDARY ENDPOINTS
Source text: ID:nBw2s6RhDa
Further company coverage: ARWR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers